Advertisement
Research Article| Volume 119, P149-154, January 2022

Download started.

Ok

Increase in the frequency of catheter-related bloodstream infections during the COVID-19 pandemic: a plea for control

  • M.J. Pérez-Granda
    Correspondence
    Corresponding author. Address: Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Madrid, 28007, Spain. Tel.: +34 91 586 84 53; fax: +34 91 504 49 06.
    Affiliations
    Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    CIBER de Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain

    Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

    Department of Nursing, School of Nursing, Physiotherapy and Podiatry, Universidad Complutense de Madrid, Madrid, Spain
    Search for articles by this author
  • C.S. Carrillo
    Affiliations
    Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
    Search for articles by this author
  • P.M. Rabadán
    Affiliations
    Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
    Search for articles by this author
  • M. Valerio
    Affiliations
    Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
    Search for articles by this author
  • M. Olmedo
    Affiliations
    Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
    Search for articles by this author
  • P. Muñoz
    Affiliations
    Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    CIBER de Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain

    Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

    Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
    Search for articles by this author
  • E. Bouza
    Affiliations
    Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    CIBER de Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain

    Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

    Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
    Search for articles by this author
Published:October 07, 2021DOI:https://doi.org/10.1016/j.jhin.2021.09.020

      Summary

      Background

      The incidence of nosocomial infections including ventilator-associated pneumonia and bacteraemia has been described during the COVID-19 pandemic. However, information regarding the impact of COVID-19 on the incidence of catheter-related bloodstream infections (CR-BSIs) is very limited.

      Aim

      To evaluate the impact of the COVID-19 pandemic in the evolution of CR-BSIs in a large hospital.

      Methods

      This was a retrospective study comparing the incidence, aetiology and outcome of CR-BSIs during the months of March to May 2019 (pre-pandemic) and 2020 (during the pandemic).

      Findings

      The number of patients with one or more CR-BSIs in 2019 and 2020 were 23 and 58, respectively (1.89 vs 5.53/1000 admissions); P<0.001. Median time from catheter implantation to demonstration of CR-BSI was 27.5 days (range 11.75–126.00 days) in the 2019 cases and 16.0 days (range 11.00–23.50 days) in the 2020 population (P=0.032).

      Conclusions

      A dramatic increase of CR-BSIs was found during the COVID-19 pandemic. Reinforcement of classic and new preventive measures is necessary.

      Keywords

      Introduction

      Catheter-related infection is one of the leading causes of bacteraemia and sepsis in developed countries and its adequate control by multi-disciplinary teams represents one of the best-quality indicators of an institution. The incidence can range from 0.8 to 18 episodes/1000 days of catheter exposure, depending on the type of patient, the type of catheter and the care provided during implantation and follow-up [
      • Stevens V.
      • Geiger K.
      • Concannon C.
      • Nelson R.E.
      • Brown J.
      • Dumyati G.
      Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections.
      ,
      • Ferrer C.
      • Almirante B.
      Venous catheter-related infections.
      ,
      • Rosenthal V.D.
      • Bat-Erdene I.
      • Gupta D.
      • Belkebir S.
      • Rajhans P.
      • Zand F.
      • et al.
      International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012-2017: Device-associated module.
      ,
      • Pittiruti M.
      • Pinelli F.
      Recommendations for the use of vascular access in the COVID-19 patients: an Italian perspective.
      ,
      • Timsit J.F.
      • Baleine J.
      • Bernard L.
      • Calvino-Gunther S.
      • Darmon M.
      • Dellamonica J.
      • et al.
      Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit.
      ].
      The COVID-19 pandemic has led to a huge increase in the workload of hospitals around the world and many patients have required long hospital stays including extended admissions to intensive care units (ICUs) [
      • Ceylan Z.
      Estimation of COVID-19 prevalence in Italy, Spain, and France.
      ,
      • Kazemi-Karyani A.
      • Safari-Faramani R.
      • Amini S.
      • Ramezani-Doroh V.
      • Berenjian F.
      • Dizaj M.Y.
      • et al.
      World one-hundred days after COVID-19 outbreak: incidence, case fatality rate, and trend.
      ,
      • Guan W.J.
      • Ni Z.Y.
      • Hu Y.
      • Liang W.H.
      • Ou C.Q.
      • He J.X.
      • et al.
      Clinical characteristics of coronavirus disease 2019 in China.
      ].
      Care for these patients has been provided under strenuous circumstances, not only because of the increased workload but also because sometimes there was a need to implicate staff with a sub-optimal degree of training with ICU patients [
      • Huang L.
      • Wang Y.
      • Liu J.
      • Ye P
      • Chen X
      • Xu H
      • et al.
      Factors influencing anxiety of health care workers in the radiology department with high exposure risk to COVID-19.
      ,
      • Sorbello M.
      • El-Boghdadly K.
      • Di Giacinto I.
      • Cataldo R.
      • Esposito C.
      • Falcetta S.
      • et al.
      The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice.
      ,
      • Scoppettuolo G.
      • Biasucci D.G.
      • Pittiruti M.
      Vascular access in COVID-19 patients: smart decisions for maximal safety.
      ].
      Under these conditions, it is not surprising that an increased incidence of nosocomially acquired infections, including ventilator-associated pneumonia and bacteraemia, has been described in some centres [
      • Cataldo M.A.
      • Tetaj N.
      • Selleri M.
      • Marchioni L.
      • Capone A.
      • Caraffa E.
      • et al.
      Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect.
      ,
      • Bonazzetti C.
      • Morena V.
      • Giacomelli A.
      • Oreni L.
      • Casalini G.
      • Galimberti L.R.
      • et al.
      Unexpectedly high frequency of enterococcal bloodstream infections in coronavirus disease 2019 patients admitted to an Italian ICU: an observational study.
      ,
      • Guan W.J.
      • Liang W.H.
      • Zhao Y.
      • Liang H.R.
      • Chen Z.S.
      • Li Y.M.
      • et al.
      Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.
      ]. Surprisingly, information regarding the impact of COVID-19 on the incidence of catheter-related bloodstream infections (CR-BSIs) is thus far limited.
      Our aim was to evaluate the impact of the COVID-19 pandemic in the evolution of CR-BSIs in a large hospital, including incidence, aetiology and outcome.

      Material and methods

      Setting

      Our institution is a general reference hospital, located in Madrid, Spain, with 1350 beds and approximately 55,000 admissions/year. The number of ICU beds is normally 70, but was expanded to 140 during the study period.

      Study design

      We performed a retrospective study in which we compared the incidence, aetiology, and outcome of CR-BSIs during the months of March to May in 2019 and 2020 (before and during the COVID-19 pandemic).

      Ethics approval and consent to participate

      The Ethics of Hospital General Universitario Gregorio Marañon approved the study. The need for informed consent for this study was waived by Ethics Committee MICRO.HGUGM.2020-030 of Hospital General Universitario Gregorio Marañon. All procedures were carried out in accordance with relevant guidelines and regulations.

      Endpoints

      The primary endpoint was the incidence of CR-BSI episodes before and during the pandemic. The secondary endpoints were the aetiology and consequences of CR-BSI during the first wave of the pandemic.

      Definitions

      CR-BSI

      Presence of bacteraemia or fungaemia in a patient with clinical manifestations of infection and no other apparent source of bloodstream infection (with the exception of the catheter). A catheter-tip culture, quantitative or semiquantitative, positive for the same micro-organism was also required [
      • Timsit J.F.
      • Baleine J.
      • Bernard L.
      • Calvino-Gunther S.
      • Darmon M.
      • Dellamonica J.
      • et al.
      Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit.
      ,
      • O'Grady N.P.
      • Alexander M.
      • Burns L.A.
      • Dellinger E.P.
      • Garland J.
      • Heard S.O.
      • et al.
      Guidelines for the prevention of intravascular catheter-related infections.
      ].

      Non–CR-BSI

      In the present study, episodes of bacteraemia with a non-documented catheter origin.

      Attributable mortality

      In the present study, death occurring within 7 days after confirmation of CR-BSI in the absence of an alternative evident cause was considered as attributable.

      Statistical analysis

      Qualitative variables are expressed as a frequency distribution. Quantitative variables are expressed as the mean and standard deviation (SD) and as the median and interquartile range (IQR) if their distribution was skewed. Normally distributed continuous variables were compared using the t-test; non-normally distributed continuous variables were compared using the Mann–Whitney test. The chi-squared or Fisher exact test was used to compare categorical variables. Statistical significance was set at P≤0.05.
      We compared the incidence rate of catheter-related bacteraemia per 1000 admissions between the two periods using Epidat version 3.1.
      Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp, Armonk, NY, USA) and Epidat 3.1.

      Results

      Hospital admissions during the study periods (1st March to 31st May 2019 and 2020) were, respectively, 12,111 and 10,479 patients. Similarly, the number of blood cultures processed by the microbiology department was, respectively, 9520 (786.06/1000 admissions) and 8802 (839.96/1000 admissions) (P<0.001), and the number of episodes of significant bloodstream infections was 358 (29.55/1000 admissions) and 379 (36.16/1000 admissions) in each three-month period in 2019 and 2020, respectively (P=0.007). The rate of contaminated blood cultures was 2.8% and 3.8% (P<0.001), before and during the pandemic.
      The number of withdrawn catheters processed for culture in our laboratory was 302 (24.93/1,000 admissions) in 2019 and 617 (58.87/1000 admissions) in 2020 (P<0.001), and the number of positive catheter tips was 59 (4.87/1,000 admissions) and 161 (15.36/1,000 admissions) (P=0.066), respectively, in 2019 and 2020 study periods.
      The number of patients with one or more CR-BSIs increased significantly in 2020 (Figure 1) (23 and 58 (1.89 vs 5.53/1000 admissions); P<0.001). The number of CR-BSI episodes in the study periods 2019 and 2020 was, respectively, 24 and 65 (1.98 vs 6.20/1000 admissions) (P<0.001). The proportion of CR-BSIs from all significant episodes of bloodstream infections was 6.7% in 2019 and 17.1% in 2020 (P<0.001).
      Figure 1
      Figure 1Incidence rate of catheter-related bloodstream infections (CR-BSIs)/1000 admissions during the study periods.
      The underlying conditions and characteristics of both populations are compared in Table I. A high proportion of the cases of CR-BSI in 2020 occurred in COVID-19 patients (77.58%), and the vast majority of episodes occurred during their ICU stay (91.37%). The median ICU stay in patients with CR-BSIs was much longer in 2020 than in 2019 (35.0 (17.0–59.7)) vs 17.0 (0.0–52.0); P=0.042).
      Table IComparison of patients with catheter-related bloodstream infections (CR-BSIs) in 2019 and 2020
      PatientsTotal

      N = 81
      2019

      N = 23
      2020

      N = 58
      P
      Median age in years, adults (IQR)65.0 (57.50–70.50)69.00 (58.00–73.00)64.50 (56.00–68.25)0.168
      Median age in years, children (IQR)0.0 (0.0–27.50)0.0 (0.0–99.00)0.5 (0.0–27.50)0.629
      ICU (%)68 (83.95)15 (65.21)53 (91.37)0.007
      Sex (%)0.010
       Male60 (74.07)12 (52.17)48 (82.75)
       Female21 (25.92)11 (47.82)10 (17.24)
      Underlying conditions (%)
       COVID-1945 (55.55)0 (0.0)45 (77.58)<0.001
       Myocardial infarction2 (2.46)0 (0.0)2 (3.44)1.000
       Congestive heart failure1 (1.23)0 (0.0)1 (1.72)1.000
       Central nervous system disease3 (3.70)2 (8.69)1 (1.72)0.193
       Chronic obstructive pulmonary disease12 (14.81)1 (4.34)11 (18.96)0.164
       Renal dysfunction7 (8.64)2 (8.69)5 (8.62)1.000
       Diabetes mellitus18 (22.22)5 (21.73)13 (22.41)1.000
       Peptic ulcer disease10 (12.34)6 (26.08)4 (6.89)0.027
       Peripheral vascular disease2 (2.46)1 (4.34)1 (1.72)0.490
       Tumour16 (19.75)11 (47.82)5 (8.62)0.001
      Median length of hospital stay in days (IQR)47.00 (29.00–83.50)35.00 (19.00–83.00)53.00 (34.75–91.75)0.059
      Median length of ICU stay in days (IQR)36.50 (21.25–65.75)17.00 (0.00–52.00)35.00 (17.00–59.70)0.042
      Other infections (%)57 (70.37)10 (43.47)47 (81.03)0.002
      Mortality (%)32 (39.50)7 (30.43)25 (43.10)0.325
      Mortality attributable to CR-BSI (N = 32) (%)12 (37.5)2 (28.57)10 (40.00)0.465
      ICU, intensive care medicine; IQR, interquartile range.
      In 2019, 10 patients developed nosocomial infection (five of them had two or more infections): six urinary tract infections, eight respiratory infections, one surgical wound infection and one cytomegalovirus disease. Of these 10 patients, nine (90%) were in the ICU. In 2020, 47 patients developed nosocomial infection (22 had two or more infections): 15 urinary tract infection, 23 respiratory infections, one surgical wound infection, 13 cytomegalovirus disease, one Clostridioides difficile infection and six bloodstream infections. Forty-six patients (97.8%) were in the ICU.
      The characteristics of the catheters in both populations are summarized in Table II. A large proportion of catheters in the 2020 patients were non-tunneled central lines (64.6%), and, of these, 78.6% were inserted into the jugular vein partially due to the prone position.
      Table IICharacteristics of the catheters
      CathetersTotal

      N = 89
      2019

      N = 24
      2020

      N = 65
      P
      Type of catheter, adults, N (%)
       Non-tunneled central venous49 (55.05)7 (29.16)42 (64.61)0.004
       Tunneled central venous12 (13.48)8 (33.33)4 (6.15)0.204
       Peripheral venous catheter3 (3.37)0 (0.0)3 (4.61)1.000
       Peripherally inserted central catheter15 (16.85)1 (4.16)14 (21.53)0.277
       Arterial10 (11.23)8 (33.33)2 (3.07)1.000
      Location of non-tunneled central venous, N=49 (%)
       Jugular35 (71.42)2 (28.57)33 (78.57)0.015
       Subclavian8 (16.32)4 (57.14)4 (9.52)0.009
       Femoral6 (12.24)1 (14.28)5 (11.90)1.00
      Catheter days, median (IQR)17.00 (11.00–28.50)27.50 (11.75–126.00)16.00 (11.00–23.50)0.032
      Catheter days, total522236371585NA
      IQR, interquartile range.
      Median time from insertion to demonstration of CR-BSIs was 27.5 days (range, 11.75 to 126.00 days) in the 2019 cases and 16.0 days (range, 11.00–23.50 days) in 2020 (P=0.032).
      The comparative aetiologies of the CR-BSI episodes in 2019 and 2020 are shown in Figure 2. We were unable to detect significant differences in the proportion of causative micro-organisms of CR-BSIs between the 2019 cases and the 2020 cases.
      Figure 2
      Figure 2Aetiology of episodes of catheter-related bloodstream infection (CR-BSI). Percentages of micro-organisms causing CR-BSI in 2019 and 2020.
      The attributable mortality of CR-BSIs, in 2019 and 2020 was 28.6% and 40.0%, respectively (P=0.465).

      Discussion

      Our results demonstrate the substantial quantitative and qualitative impact of the COVID-19 pandemic in CR-BSI. The incidence of CR-BSI increased at least three-fold during the first 3 months of the COVID-19 pandemic in our institution.
      The damage caused by the COVID-19 pandemic in different aspects of healthcare and infection control has been devastating, although not yet sufficiently analysed [
      • Ball S.
      • Banerjee A.
      • Berry C.
      • Boyle J.R.
      • Bray B.
      • Bradlow W.
      • et al.
      Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK.
      ,
      • Shapiro L.I.
      • Kajita G.R.
      • Arnsten J.H.
      • Tomer Y.
      Toward better preparedness for the next pandemic.
      ,
      • Cohen A.
      • Selles R.W.
      • De Ridder W.A.
      • Ter Stege M.H.P.
      • Souer J.S.
      • Wouters R.M.
      What is the impact of the COVID-19 pandemic on quality of life and other patient-reported outcomes? An analysis of the hand-wrist study cohort.
      ,
      • Tan E.
      • Song J.
      • Deane A.M.
      • Plummer M.P.
      Global impact of coronavirus disease 2019 infection requiring admission to the ICU: a systematic review and meta-analysis.
      ,
      • Harrison D.
      • Muradali K.
      • El Sahly H.
      • Bozkurt B.
      • Jneid H.
      Impact of the SARS-CoV-2 pandemic on health-care workers.
      ]. At the beginning of the pandemic, it was already anticipated that patients with severe COVID-19 would develop superinfections, most commonly pneumonia due to nosocomial bacteria and invasive aspergillosis [
      • Dupont D.
      • Menotti J.
      • Turc J.
      • Miossec C.
      • Wallet F.
      • Richard J.C.
      • et al.
      Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19).
      ,
      • Clancy C.J.
      • Nguyen M.H.
      COVID-19, superinfections and antimicrobial development: what can we expect?.
      ]. This was confirmed, and, nosocomial secondary infections have been estimated to have occurred in between 7% and 14.3% of hospitalized COVID-19 patients (95% confidence interval, 9.6–18.9%) [
      • Langford B.J.
      • So M.
      • Raybardhan S.
      • Leung V.
      • Westwood D.
      • MacFadden D.R.
      • et al.
      Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.
      ,
      • Garcia-Vidal C.
      • Sanjuan G.
      • Moreno-García E.
      • Puerta-Alcalde P.
      • Garcia-Pouton N.
      • Chumbita M.
      • et al.
      Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.
      ]; these infections are more frequent in ICU patients [
      • Zhang H.
      • Zhang Y.
      • Wu J.
      • Li Y.
      • Zhou X.
      • Li X.
      • et al.
      Risks and features of secondary infections in severe and critical ill COVID-19 patients.
      ,
      • Barrasa H.
      • Rello J.
      • Tejada S.
      • Martín A.
      • Balziskueta G.
      • Vinuesa C.
      • et al.
      SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
      ].
      Most common secondary infections in this population are nosocomial pneumonia, mainly associated with mechanical ventilation [
      • Ceccarelli G.
      • Alessandri F.
      • Oliva A.
      • Dell'Isola S.
      • Rocco M.
      • Ruberto F.
      • et al.
      Superinfections in patients treated with Teicoplanin as anti-SARSCoV2 agent.
      ], and bloodstream infections. The most frequent micro-organisms, as expected, were Staphylococcus aureus, Enterococcus spp., Escherichia coli, and Pseudomonas aeruginosa [
      • Garcia-Vidal C.
      • Sanjuan G.
      • Moreno-García E.
      • Puerta-Alcalde P.
      • Garcia-Pouton N.
      • Chumbita M.
      • et al.
      Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.
      ]. The infections frequently involved multi-drug-resistant micro-organisms [
      • Zhang H.
      • Zhang Y.
      • Wu J.
      • Li Y.
      • Zhou X.
      • Li X.
      • et al.
      Risks and features of secondary infections in severe and critical ill COVID-19 patients.
      ,
      • Barrasa H.
      • Rello J.
      • Tejada S.
      • Martín A.
      • Balziskueta G.
      • Vinuesa C.
      • et al.
      SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
      ,
      • Ceccarelli G.
      • Alessandri F.
      • Oliva A.
      • Dell'Isola S.
      • Rocco M.
      • Ruberto F.
      • et al.
      Superinfections in patients treated with Teicoplanin as anti-SARSCoV2 agent.
      ,
      • Nori P.
      • Cowman K.
      • Chen V.
      • Bartash R.
      • Szymczak W.
      • Madaline T.
      • et al.
      Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.
      ,
      • Wu C.P.
      • Adhi F.
      • Highland K.
      Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19.
      ]. Surprisingly, and despite overuse of antibiotics during the pandemic, preliminary data suggest that the incidence of C. difficile infection decreased in COVID-19 cases [
      • LeRose J.
      • Sandhu A.
      • Polistico J.
      • Ellsworth J.
      • Cranis M.
      • Jabbo L.
      • et al.
      The impact of COVID-19 response on central line associated bloodstream infections and blood culture contamination rates at a tertiary care center in the Greater Detroit area.
      ,
      • Ponce-Alonso M.
      • Sáez de la Fuente J.
      • Rincón-Carlavilla A.
      • Moreno-Nunez P.
      • Martínez-García L.
      • Escudero-Sánchez R.
      • et al.
      Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection.
      ,
      • Bentivegna E.
      • Alessio G.
      • Spuntarelli V.
      • Luciani M.
      • Santino I.
      • Simmaco M.
      • et al.
      Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection.
      ,
      • Heard K.L.
      • Hughes S.
      • Mughal N.
      • Moore L.S.P.
      COVID-19 and fungal superinfection.
      ].
      Fungal superinfections are also a considerable problem [
      • Heard K.L.
      • Hughes S.
      • Mughal N.
      • Moore L.S.P.
      COVID-19 and fungal superinfection.
      ,
      • Nestler M.
      • Godbout E.
      • Lee K.
      • Kim J.
      • Noda A.J.
      • Taylor P.
      • et al.
      Fungal superinfection in patients with COVID-19: role of antifungal stewardship?.
      ] and include invasive candidiasis and candidaemia [
      • Arastehfar A.
      • Carvalho A.
      • Nguyen M.H.
      • Hedayati M.T.
      • Netea M.G.
      • Perlin D.S.
      • et al.
      COVID-19-associated Candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?.
      ], coronavirus-associated pulmonary aspergillosis [
      • Bassetti M.
      • Giacobbe D.R.
      • Grecchi C.
      • Rebuffi C.
      • Zuccaro V.
      • Scudeller L.
      Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis.
      ,
      • Blaize M.
      • Mayaux J.
      • Nabet C.
      • Lampros A.
      • Marcelin A.G.
      • Thellier M.
      • et al.
      Fatal invasive Aspergillosis and coronavirus disease in an immunocompetent patient.
      ,
      • Arastehfar A.
      • Carvalho A.
      • van de Veerdonk F.L.
      • Jenks J.D.
      • Koehler P.
      • Krause R.
      • et al.
      COVID-19 Associated pulmonary aspergillosis (CAPA) – from immunology to treatment.
      ,
      • Machado M.
      • Valerio M.
      • Álvarez-Uría A.
      • Olmedo M.
      • Veintimilla C.
      • Padilla B.
      • et al.
      Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity.
      ], and even Saccharomyces fungaemia [
      • Ventoulis I.
      • Sarmourli T.
      • Amoiridou P.
      • Mantzana P.
      • Exindari M.
      • Gioula G.
      • et al.
      Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU.
      ].
      Interestingly, data on episodes of bacteraemia were contradictory in the initial reports of the pandemic period and usually do not specify the policy of blood cultures drawing in different institutions [
      • Sepulveda J.
      • Westblade L.F.
      • Whittier S.
      • Satlin M.J.
      • Greendyke W.G.
      • Aaron J.G.
      • et al.
      Bacteremia and blood culture utilization during COVID-19 surge in New York City.
      ,
      • Yu D.
      • Ininbergs K.
      • Hedman K.
      • Giske C.G.
      • Strålin K.
      • Özenci V.
      Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19.
      ]. However, it seems clear that prolonged hospital stay, in ICUs, has led most authors to report an increase in episodes of bacteraemia [
      • Engsbro A.L.
      • Israelsen S.B.
      • Pedersen M.
      • Tingsgaard S.
      • Lisby G.
      • Andersen C.
      • et al.
      Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia.
      ].
      Our series includes 81 patients with proven CR-BSIs and compared a similar time period in 2019 and 2020; we found that the frequency of CR-BSIs increased three-fold during the COVID-19 period. Very recently, Le Rose et al. [
      • LeRose J.
      • Sandhu A.
      • Polistico J.
      • Ellsworth J.
      • Cranis M.
      • Jabbo L.
      • et al.
      The impact of COVID-19 response on central line associated bloodstream infections and blood culture contamination rates at a tertiary care center in the Greater Detroit area.
      ] reported an increase in the incidence of vascular catheter-related infections during the pandemic. The authors analysed a series of bloodstream infections, with no clear portal of entry, that they related with central-line-associated bloodstream infection (CLABSI). Of the 36 patients who developed CLABSI, six (17%) were in a pre-COVID-19 cohort, while 30 (83%) were in the COVID-19 cohort. The average monthly CLABSI rate increased from 0.40 to 1.7 during COVID-19 (P<0.01). Data from an Italian institution showed that 30% of all BSI episodes during the COVID-19 pandemic originated in endovascular catheters [
      • Giacobbe D.R.
      • Battaglini D.
      • Ball L.
      • Brunetti I.
      • Bruzzone B.
      • Codda G.
      • et al.
      Bloodstream infections in critically ill patients with COVID-19.
      ]. In our study, this proportion is lower because we included only microbiologically confirmed episodes (CR-BSIs).
      In our study 93.7% of the patients with CR-BSI during the pandemic period were in the ICU, in addition these patients received high doses of steroids and most of them were in the prone position, all risk factors for developing more nosocomial infections as described in other studies [
      • Engsbro A.L.
      • Israelsen S.B.
      • Pedersen M.
      • Tingsgaard S.
      • Lisby G.
      • Andersen C.
      • et al.
      Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia.
      ,
      • Giacobbe D.R.
      • Battaglini D.
      • Ball L.
      • Brunetti I.
      • Bruzzone B.
      • Codda G.
      • et al.
      Bloodstream infections in critically ill patients with COVID-19.
      ]. The use of the prone position to improve ventilation is used in many ICUs, and poses difficulties for both insertion and care of endovascular catheters and has been related to higher risk of CVC infectious complications [
      • Yang X.
      • Yu Y.
      • Xu J.
      • Shu H.
      • Xia J.
      • Liu H.
      • et al.
      Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
      ,
      • Louis G.
      • Belveyre T.
      • Jacquot A.
      • Hochard H.
      • Aissa N.
      • Kimmoun A.
      • et al.
      Infection related catheter complications in patients undergoing prone positioning for acute respiratory distress syndrome: an exposed/unexposed study.
      ].
      Patients who developed CLABSI in the pre–COVID-19 cohort had a median length of stay of 19 days compared with patients in the COVID-19 cohort, who had a median length of stay of 27 days (P=0.12) [
      • LeRose J.
      • Sandhu A.
      • Polistico J.
      • Ellsworth J.
      • Cranis M.
      • Jabbo L.
      • et al.
      The impact of COVID-19 response on central line associated bloodstream infections and blood culture contamination rates at a tertiary care center in the Greater Detroit area.
      ]. However, in our study, despite a longer ICU stay, episodes of CR-BSI occurred earlier after catheter insertion than in 2019. If we combine these findings with an increased rate of contaminated blood cultures and a higher proportion of CR-BSI caused by coagulase-negative staphylococci, we can conclude that catheter insertion and care worsened.
      Other risk factors reported in the literature include the use of corticosteroids and tocilizumab, although we have little insight into the role that other risk factors may have in these patients [
      • Giacobbe D.R.
      • Battaglini D.
      • Ball L.
      • Brunetti I.
      • Bruzzone B.
      • Codda G.
      • et al.
      Bloodstream infections in critically ill patients with COVID-19.
      ].
      In our study, the micro-organisms causing CR-BSI were mainly Gram-positive. Other authors, analysing the aetiologies of CLABSI in a COVID-19 cohort, reported that 53.3% were caused by Gram-positive bacteria, followed by 26.7% fungal and 20% Gram-negative bacteria [
      • LeRose J.
      • Sandhu A.
      • Polistico J.
      • Ellsworth J.
      • Cranis M.
      • Jabbo L.
      • et al.
      The impact of COVID-19 response on central line associated bloodstream infections and blood culture contamination rates at a tertiary care center in the Greater Detroit area.
      ].
      The main limitation of our study is that it was performed in a single hospital and further studies with multi-centre data would be welcome. While our study reflects findings from a single hospital, we believe that it appropriately quantifies a problem that may well have affected many centres throughout the world.
      We hope that our findings will contribute to urge health professionals to immediately reinforce nosocomial infection control measures. These figures should and can be lowered [
      • Timsit J.F.
      • Baleine J.
      • Bernard L.
      • Calvino-Gunther S.
      • Darmon M.
      • Dellamonica J.
      • et al.
      Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit.
      ,
      • Chun T.T.
      • Judelson D.R.
      • Rigberg D.
      • Lawrence P.F.
      • Cuff R.
      • Shalhub S.
      • et al.
      Managing central venous access during a health care crisis.
      ].

      Acknowledgements

      We thank Thomas O'Boyle for his help in the preparation of the manuscript.

      Author contributions

      E.B. and M.J.P.G. participated in the conception and design of the study, carried out the analysis, interpreted the data and drafted the manuscript. C.S., P.M.R., M.V., M.O. and PM collected the samples and data and participated in drafting the manuscript. All of the authors read and approved the final version of the manuscript.

      Conflict of interest statement

      The authors declare no conflicts of interest.

      Funding sources

      This study was supported in part by CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain; by grants from the ISCIII (PI20/00575) II-PI-ENF-1-2019 and the European Regional Development Fund (FEDER) “A way of making Europe”. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

      References

        • Stevens V.
        • Geiger K.
        • Concannon C.
        • Nelson R.E.
        • Brown J.
        • Dumyati G.
        Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections.
        Clin Microbiol Infect. 2014; 20: O318-O324
        • Ferrer C.
        • Almirante B.
        Venous catheter-related infections.
        Enferm Infecc Microbiol Clin. 2014; 32: 115-124
        • Rosenthal V.D.
        • Bat-Erdene I.
        • Gupta D.
        • Belkebir S.
        • Rajhans P.
        • Zand F.
        • et al.
        International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012-2017: Device-associated module.
        Am J Infect Control. 2020; 48: 423-432
        • Pittiruti M.
        • Pinelli F.
        Recommendations for the use of vascular access in the COVID-19 patients: an Italian perspective.
        Crit Care. 2020; 24: 269
        • Timsit J.F.
        • Baleine J.
        • Bernard L.
        • Calvino-Gunther S.
        • Darmon M.
        • Dellamonica J.
        • et al.
        Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit.
        Ann Intensive Care. 2020; 10: 118
        • Ceylan Z.
        Estimation of COVID-19 prevalence in Italy, Spain, and France.
        Sci Total Environ. 2020; 729: 138817
        • Kazemi-Karyani A.
        • Safari-Faramani R.
        • Amini S.
        • Ramezani-Doroh V.
        • Berenjian F.
        • Dizaj M.Y.
        • et al.
        World one-hundred days after COVID-19 outbreak: incidence, case fatality rate, and trend.
        J Educ Health Promot. 2020; 9: 199
        • Guan W.J.
        • Ni Z.Y.
        • Hu Y.
        • Liang W.H.
        • Ou C.Q.
        • He J.X.
        • et al.
        Clinical characteristics of coronavirus disease 2019 in China.
        N Engl J Med. 2020; 382: 1708-1720
        • Huang L.
        • Wang Y.
        • Liu J.
        • Ye P
        • Chen X
        • Xu H
        • et al.
        Factors influencing anxiety of health care workers in the radiology department with high exposure risk to COVID-19.
        Med Sci Monit. 2020; 26e926008
        • Sorbello M.
        • El-Boghdadly K.
        • Di Giacinto I.
        • Cataldo R.
        • Esposito C.
        • Falcetta S.
        • et al.
        The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice.
        Anaesthesia. 2020; 75: 724-732
        • Scoppettuolo G.
        • Biasucci D.G.
        • Pittiruti M.
        Vascular access in COVID-19 patients: smart decisions for maximal safety.
        J Vasc Access. 2020; 21: 408-410
        • Cataldo M.A.
        • Tetaj N.
        • Selleri M.
        • Marchioni L.
        • Capone A.
        • Caraffa E.
        • et al.
        Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect.
        J Glob Antimicrob Resist. 2020; 23: 290-291
        • Bonazzetti C.
        • Morena V.
        • Giacomelli A.
        • Oreni L.
        • Casalini G.
        • Galimberti L.R.
        • et al.
        Unexpectedly high frequency of enterococcal bloodstream infections in coronavirus disease 2019 patients admitted to an Italian ICU: an observational study.
        Crit Care Med. 2021; 49: e31-40
        • Guan W.J.
        • Liang W.H.
        • Zhao Y.
        • Liang H.R.
        • Chen Z.S.
        • Li Y.M.
        • et al.
        Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.
        Eur Respir J. 2020; 55: 2000547
        • O'Grady N.P.
        • Alexander M.
        • Burns L.A.
        • Dellinger E.P.
        • Garland J.
        • Heard S.O.
        • et al.
        Guidelines for the prevention of intravascular catheter-related infections.
        Clin Infect Dis. 2011; 52: e162-e193
        • Ball S.
        • Banerjee A.
        • Berry C.
        • Boyle J.R.
        • Bray B.
        • Bradlow W.
        • et al.
        Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK.
        Heart. 2020; 106: 1890-1897
        • Shapiro L.I.
        • Kajita G.R.
        • Arnsten J.H.
        • Tomer Y.
        Toward better preparedness for the next pandemic.
        J Clin Invest. 2020; 130: 4543-4545
        • Cohen A.
        • Selles R.W.
        • De Ridder W.A.
        • Ter Stege M.H.P.
        • Souer J.S.
        • Wouters R.M.
        What is the impact of the COVID-19 pandemic on quality of life and other patient-reported outcomes? An analysis of the hand-wrist study cohort.
        Clin Orthop Relat Res. 2021; 479: 335-345
        • Tan E.
        • Song J.
        • Deane A.M.
        • Plummer M.P.
        Global impact of coronavirus disease 2019 infection requiring admission to the ICU: a systematic review and meta-analysis.
        Chest. 2021; 159: 524-536
        • Harrison D.
        • Muradali K.
        • El Sahly H.
        • Bozkurt B.
        • Jneid H.
        Impact of the SARS-CoV-2 pandemic on health-care workers.
        Hosp Pract. 2020; 48: 161-164
        • Dupont D.
        • Menotti J.
        • Turc J.
        • Miossec C.
        • Wallet F.
        • Richard J.C.
        • et al.
        Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19).
        Med Mycol. 2021; 59: 110-114
        • Clancy C.J.
        • Nguyen M.H.
        COVID-19, superinfections and antimicrobial development: what can we expect?.
        Clin Infect Dis. 2020; 71: 2736-2743
        • Langford B.J.
        • So M.
        • Raybardhan S.
        • Leung V.
        • Westwood D.
        • MacFadden D.R.
        • et al.
        Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.
        Clin Microbiol Infect. 2020; 26: 1622-1629
        • Garcia-Vidal C.
        • Sanjuan G.
        • Moreno-García E.
        • Puerta-Alcalde P.
        • Garcia-Pouton N.
        • Chumbita M.
        • et al.
        Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.
        Clin Microbiol Infect. 2021; 27: 83-88
        • Zhang H.
        • Zhang Y.
        • Wu J.
        • Li Y.
        • Zhou X.
        • Li X.
        • et al.
        Risks and features of secondary infections in severe and critical ill COVID-19 patients.
        Emerg Microbes Infect. 2020; 9: 1958-1964
        • Barrasa H.
        • Rello J.
        • Tejada S.
        • Martín A.
        • Balziskueta G.
        • Vinuesa C.
        • et al.
        SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
        Anaesth Crit Care Pain Med. 2020; 39: 553-561
        • Ceccarelli G.
        • Alessandri F.
        • Oliva A.
        • Dell'Isola S.
        • Rocco M.
        • Ruberto F.
        • et al.
        Superinfections in patients treated with Teicoplanin as anti-SARSCoV2 agent.
        Eur J Clin Invest. 2021; 51e13418
        • Nori P.
        • Cowman K.
        • Chen V.
        • Bartash R.
        • Szymczak W.
        • Madaline T.
        • et al.
        Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.
        Infect Control Hosp Epidemiol. 2021; 42: 84-88
        • Wu C.P.
        • Adhi F.
        • Highland K.
        Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19.
        Cleve Clin J Med. 2020; 87: 659-663
        • LeRose J.
        • Sandhu A.
        • Polistico J.
        • Ellsworth J.
        • Cranis M.
        • Jabbo L.
        • et al.
        The impact of COVID-19 response on central line associated bloodstream infections and blood culture contamination rates at a tertiary care center in the Greater Detroit area.
        Infect Control Hosp. 2021; 42: 997-1000
        • Ponce-Alonso M.
        • Sáez de la Fuente J.
        • Rincón-Carlavilla A.
        • Moreno-Nunez P.
        • Martínez-García L.
        • Escudero-Sánchez R.
        • et al.
        Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection.
        Infect Control Hosp Epidemiol. 2021; 42: 406-410
        • Bentivegna E.
        • Alessio G.
        • Spuntarelli V.
        • Luciani M.
        • Santino I.
        • Simmaco M.
        • et al.
        Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection.
        Am J Infect Control. 2021; 49: 640-642
        • Heard K.L.
        • Hughes S.
        • Mughal N.
        • Moore L.S.P.
        COVID-19 and fungal superinfection.
        Lancet Microbe. 2020; 1: e107
        • Nestler M.
        • Godbout E.
        • Lee K.
        • Kim J.
        • Noda A.J.
        • Taylor P.
        • et al.
        Fungal superinfection in patients with COVID-19: role of antifungal stewardship?.
        Am J Infect Control. 2021; 49: 279-280
        • Arastehfar A.
        • Carvalho A.
        • Nguyen M.H.
        • Hedayati M.T.
        • Netea M.G.
        • Perlin D.S.
        • et al.
        COVID-19-associated Candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?.
        J Fungi (Basel). 2020; 6: 211
        • Bassetti M.
        • Giacobbe D.R.
        • Grecchi C.
        • Rebuffi C.
        • Zuccaro V.
        • Scudeller L.
        Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis.
        J Infect. 2020; 81: 131-146
        • Blaize M.
        • Mayaux J.
        • Nabet C.
        • Lampros A.
        • Marcelin A.G.
        • Thellier M.
        • et al.
        Fatal invasive Aspergillosis and coronavirus disease in an immunocompetent patient.
        Emerg Infect Dis. 2020; 26: 1636-1637
        • Arastehfar A.
        • Carvalho A.
        • van de Veerdonk F.L.
        • Jenks J.D.
        • Koehler P.
        • Krause R.
        • et al.
        COVID-19 Associated pulmonary aspergillosis (CAPA) – from immunology to treatment.
        J Fungi (Basel). 2020; 6: 91
        • Machado M.
        • Valerio M.
        • Álvarez-Uría A.
        • Olmedo M.
        • Veintimilla C.
        • Padilla B.
        • et al.
        Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity.
        Mycoses. 2021; 64: 132-143
        • Ventoulis I.
        • Sarmourli T.
        • Amoiridou P.
        • Mantzana P.
        • Exindari M.
        • Gioula G.
        • et al.
        Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU.
        J Fungi (Basel). 2020; 6: 98
        • Sepulveda J.
        • Westblade L.F.
        • Whittier S.
        • Satlin M.J.
        • Greendyke W.G.
        • Aaron J.G.
        • et al.
        Bacteremia and blood culture utilization during COVID-19 surge in New York City.
        J Clin Microbiol. 2020; 58 (e00875-20)
        • Yu D.
        • Ininbergs K.
        • Hedman K.
        • Giske C.G.
        • Strålin K.
        • Özenci V.
        Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19.
        PLos One. 2020; 15e0242533
        • Engsbro A.L.
        • Israelsen S.B.
        • Pedersen M.
        • Tingsgaard S.
        • Lisby G.
        • Andersen C.
        • et al.
        Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia.
        Infect Dis (Lond). 2020; 52: 919-922
        • Giacobbe D.R.
        • Battaglini D.
        • Ball L.
        • Brunetti I.
        • Bruzzone B.
        • Codda G.
        • et al.
        Bloodstream infections in critically ill patients with COVID-19.
        Eur J Clin Invest. Oct 2020; 50e13319
        • Yang X.
        • Yu Y.
        • Xu J.
        • Shu H.
        • Xia J.
        • Liu H.
        • et al.
        Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
        Lancet Respir Med. 2020; 8: 475-481
        • Louis G.
        • Belveyre T.
        • Jacquot A.
        • Hochard H.
        • Aissa N.
        • Kimmoun A.
        • et al.
        Infection related catheter complications in patients undergoing prone positioning for acute respiratory distress syndrome: an exposed/unexposed study.
        BMC Infect Dis. 2021; 21: 534
        • Chun T.T.
        • Judelson D.R.
        • Rigberg D.
        • Lawrence P.F.
        • Cuff R.
        • Shalhub S.
        • et al.
        Managing central venous access during a health care crisis.
        J Vasc Surg. 2020; 72: 1184-1195